Patents To Gene Sequences May Cover Plants And Seeds Containing The Patented Sequences
Client Alert | 1 min read | 02.15.08
A Federal Circuit panel, in Monsanto Company v. Loren David (No. 07-1104 February 5, 2008), affirms a district court's finding of patent infringement. In so doing, the Court holds that a patent on a gene sequence entitles the holder of the patent to enforce its grant of exclusivity against growers of plant varieties that contain the patented gene sequence.
Monsanto’s patent covers a gene sequence that confers resistance to glyphosate herbicides. Monsanto distributes seeds containing the patented gene sequence by authorizing various companies to produce the seeds and sell them to farmers. David purchased the seed and signed a “Technology Agreement” which prohibited David from planting seeds produced from the purchased seed. David subsequently violated the Technology Agreement by planting seed produced by the seed. Monsanto sued for patent infringement. At trial, the district court found, inter alia, that David infringed Monsanto’s patent.
The Federal Circuit panel agrees with Monsanto’s position that patents to genetic material may be read on plants and seeds containing the patented genetic material and that those who save such seed are liable for infringement. In affirming the district courts decision, the Federal Circuit holds that Monsanto’s patent “covering the gene sequence is infringed by planting a seed containing the gene sequence. The gene itself is being used in the planting, an infringing act.”
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
